← board
LSBCF
distress 5/10 · elevated risk$0.070%today-95% from 52w high
Revenue
$86M
Liquidity
$15M
Runway
0.9 yrs
Shares 1y
—
Price & events
-92.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
-33.0%
1M
+48.9%
3M
-92.1%
6M
-92.7%
1Y
—
2Y
—
5Y
-98.1%
All
Overview
- Volume
- 0
- 52 Week Range
- $0.03 – $1.38
- Float Shares
- 5.06M
- Short %
- 0.14%
- % Held by Insiders
- 88.42%
- % Held by Institutions
- 1.47%
- Beta
- 1.01
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.